Massive 2,000-Patient study tracks new heart drug in everyday use

This study aims to understand how a recently approved medication called acoramidis works for patients with ATTR amyloidosis cardiomyopathy in real-world settings, outside of controlled clinical trials. Researchers will observe up to 2,000 adults across Europe who are starting this treatment as part of their normal care. The goal is to collect information on patient characteristics, treatment patterns, safety, and how the drug affects patients' daily lives and heart health.